Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients
NCT ID: NCT00461617
Last Updated: 2008-10-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
291 participants
INTERVENTIONAL
2006-08-31
2007-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment
NCT00213070
Dose Ranging Study of Albiglutide in Japanese Subjects
NCT01098461
Double-Blind Study of Miglitol in Japanese With type2 Diabetes
NCT00380822
Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin
NCT00213122
Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)
NCT01545388
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
Nateglinide 120 mg TID
Mitiglinide
10mg tablet, 10mg TID
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mitiglinide
10mg tablet, 10mg TID
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients who require treatment with insulin
* Patients with severe diabetic complications (neuropathy, retinopathy or nephropathy)
* Patients with severe ketosis, diabetic coma or precoma
* Patients complicated with severe hepatic diseases
* Patients complicated with severe renal diseases
* Patients complicated with severe hypertension
* Patients complicated with severe cardiac disease
* Pregnant women or women possible to be pregnant, nursing women, or women who want to become pregnant during the study period
25 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kissei Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhongshan Hospital, Fudan University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xin Gao, Professor
Role: PRINCIPAL_INVESTIGATOR
Endocrinology Dept. of Fudan University Zhongshan Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KAD1301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.